Active	Status	Sponsor type	Region	Phase	Filter
2 Active 2 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
rebastinib (DCC-2036) / Ono Pharma
DCC-2036-01-003, NCT03601897: A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors From P2 part for advanced solid tumors at ESMO 2020 Sep 2020 - Sep 2020: From P2 part for advanced solid tumors at ESMO 2020 Data in combination with paclitaxel for advanced ovarian cancer Sep 2020 - Sep 2020: Data in combination with paclitaxel for advanced ovarian cancer Data from Part 2 of a trial in combination with paclitaxel for advanced or metastatic platinum-resistant ovarian cancer at ESMO 2020 Sep 2020 - Sep 2020: Data from Part 2 of a trial in combination with paclitaxel for advanced or metastatic platinum-resistant ovarian cancer at ESMO 2020 From trial in combination with paclitaxel for advanced endometrial cancer May 2020 - May 2020: From trial in combination with paclitaxel for advanced endometrial cancer Preliminary data in combination with paclitaxel in advanced endometrial cancer at the ASCO 2020 May 2020 - May 2020: Preliminary data in combination with paclitaxel in advanced endometrial cancer at the ASCO 2020 From part1 of P1/2 trial for solid tumors at AACR-NCI-EORTC 2019 Oct 2019 - Oct 2019: From part1 of P1/2 trial for solid tumors at AACR-NCI-EORTC 2019 From part 1 of P1b/2 trial in combination with paclitaxel for metastatic solid tumors at AACR-NCI-EORTC 2019 Oct 2019 - Oct 2019: From part 1 of P1b/2 trial in combination with paclitaxel for metastatic solid tumors at AACR-NCI-EORTC 2019 More	Completed	1b/2	177	US	rebastinib, DCC-2036, Paclitaxel	Deciphera Pharmaceuticals LLC	Locally Advanced or Metastatic Solid Tumor	05/22	05/22
NCT03717415: A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors Data from dose escalation phase of a trial in combination with carboplatin for advanced or metastatic solid tumors at ESMO 2020 Sep 2020 - Oct 2020: Data from dose escalation phase of a trial in combination with carboplatin for advanced or metastatic solid tumors at ESMO 2020 From trial in combination with carboplatin for metastatic solid tumors at ESMO 2020 Sep 2020 - Sep 2020: From trial in combination with carboplatin for metastatic solid tumors at ESMO 2020	Completed	1/2	117	US	rebastinib, DCC-2036, Carboplatin	Deciphera Pharmaceuticals LLC	Locally Advanced or Metastatic Solid Tumor	05/22	11/22